Trading In Noven Common Stock Halted

FDA Advisory Committee Meeting Today on Daytrana™

-- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced that NASDAQ has halted trading of Noven common stock effective this morning, December 2, 2005. The Psychopharmacologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the amended New Drug Application for Daytrana™ (methylphenidate transdermal system).

Daytrana™, licensed globally to Shire plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See www.noven.com for additional information.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
305-253-1916